Sonoma Pharmaceuticals (SNOA) Change in Accured Expenses (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Change in Accured Expenses came in at -$276000.0 in Q1 2026, down 241.54% year-on-year from $195000.0 in Q1 2025, and down 545.16% quarter-over-quarter from $62000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$276000.0 for Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 241.54% year-over-year to -$276000.0 in Q1 2026; TTM through Mar 2026 was -$100000.0, a 151.55% decrease from a year earlier, with the FY2026 full-year figure at -$100000.0, down 151.55% from the prior year.
- Change in Accured Expenses eased to -$276000.0 in Q1 2026 per SNOA's latest filing, from $62000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $598000.0 in Q3 2025 and bottomed at -$484000.0 in Q2 2025.
- The 5-year median for Change in Accured Expenses is $53000.0 (2024), against an average of $57941.2.
- Biggest YoY gain for Change in Accured Expenses was 1200.0% in 2025; the steepest drop was 1013.21% in 2025.
- Year by year, Change in Accured Expenses stood at $390000.0 in 2022, then plunged by 184.62% to -$330000.0 in 2023, then surged by 69.7% to -$100000.0 in 2024, then jumped by 162.0% to $62000.0 in 2025, then tumbled by 545.16% to -$276000.0 in 2026.
- Per Business Quant, the three latest SNOA Change in Accured Expenses figures stand at -$276000.0 (Q1 2026), $62000.0 (Q4 2025), and $598000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | -276,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -276,000.00 |
| Mar 31, 2026 | -276,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Sep 30, 2025 | 598,000.00 |
| Jun 30, 2025 | -484,000.00 |
| Jun 30, 2025 | -484,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 53,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Mar 31, 2024 | 448,000.00 |
| Dec 31, 2023 | -330,000.00 |
| Dec 31, 2023 | -330,000.00 |